DGAP-News: MOLOGEN AG / Key word(s): Study results
PRESS RELEASE N 13 / 2019 of 8/5/2019
- Primary endpoint not met: median overall survival of 22 months in lefitolimod group compared to 21.9 months in control group; p=0.2765; hazard ratio HR: 1.12 (95% CI: 0.91 - 1.38)
- No new safety signals detected
- Future focus on combination approaches for both lefitolimod and the first clinical candidate from the EnanDIM(R) family
Dr med Stefan M. Manth, CEO of MOLOGEN, noted: "We are disappointed with these top-line results and will now analyze the bountiful data coming out of IMPALA in depth. We will then build on these analyses from IMPALA to further inform the development of lefitolimod and its successor molecules from the EnanDIM(R) platform for cancer and HIV patients. We are grateful to the patients and investigators for their participation in this important study."
Dr med Matthias Baumann, CMO of MOLOGEN, stated: "Unfortunately the positive results in our single agent lefitolimod phase II IMPACT study did not translate into a successful outcome of our phase III IMPALA trial despite the fact that all learnings have been incorporated into the trial design. In contrast to the time when the IMPALA design was conceived, it now appears that for successful anti-cancer immunotherapies a combination approach is of paramount importance. Due to the large body of evidence indicating the potential of TLR9 agonism in this context we remain committed to the further development of our candidates."
The detailed data from this first top line analysis of the IMPALA trial will be submitted for presentation at an upcoming international scientific congress.
Further to the IMPALA single-agent approach, lefitolimod is currently being evaluated in a phase I/II clinical study in combination with the checkpoint inhibitor Yervoy(R) (ipilimumab) in a broader variety of solid tumors. The study is being conducted at the renowned MD Anderson Cancer Center, Texas, USA. In addition to studies in the field of oncology, lefitolimod has also been tested in HIV patients in a phase Ib/IIa study, the TEACH trial. Based on the encouraging study results, lefitolimod will be investigated in a phase IIa combination study, the TITAN trial, in HIV-infected patients in combination with innovative virus-neutralizing antibodies developed by the Rockefeller University in New York, USA. The trial will be conducted in cooperation with the Aarhus University Hospital in Denmark, which was also the academic partner of MOLOGEN in the TEACH trial. TITAN is funded by the US biotech company Gilead Inc. Furthermore, plans for another clinical combination study in HIV with a prominent US center are at an advanced stage.
The next generation TLR9 agonistic molecules of the EnanDIM(R)-family coming out of the research labs of MOLOGEN offer additional potential for development in various cancer indications and HIV. A first clinical candidate from the EnanDIM(R) platform is presently in late pre-clinical testing and expected to launch into clinical development in oncology at the end of 2019.
Checkpoint inhibitors alone are expected to generate sales of approximately US$ 25 billion by 2022 (acc. to Research and Markets) in a growing variety of indications. However, the greatest potential of checkpoint inhibitors is still to be realized, i.e. with adequate combination partners to target indications non-amenable to checkpoint inhibitor monotherapy. Estimates from the market research organization Research and Markets project that the market for cancer immunotherapies could rise to more than US$100 billion by 2024.
Background to the IMPALA study
The study is conducted in collaboration with three highly profiled national collaborative study groups: Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany, Grupo Español de Tratamiento de Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France.
For more information on IMPALA please visit www.clinicaltrials.gov.
The focus of MOLOGEN's development is on DNA-based TLR9 agonists, where it has consistently been ahead of the course. This includes the lead compound, the immunotherapy lefitolimod, and its next generation molecules EnanDIM(R), building the foundation for a next generation immunotherapy platform in areas of unmet need.
Forthcoming milestones include: the start of the TITAN study in HIV, the start of the clinical development of EnanDIM(R) and additional combination studies in cancer, including one with our strategic partner Oncologie Inc., which are in an advanced planning stage.
MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.
05.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||030 / 841788-0|
|Fax:||030 / 841788-50|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||851921|
|End of News||DGAP News Service|